I came to know because another paid subscriber requested report, all paid subscriber can request 1 report every quarter by DM

This transforms lumpy hardware revenues (₹800–1,000 per meter, one-time) into sticky long-term cash flows (₹30–50 per meter per month × 10 years). With 9.1 crore meters deployed and targeting 18 crore by FY26, the recurring monthly OpEx revenue building up behind the current project execution is the business's hidden long-term asset.

Read more

Travel Food Services Limited (TFS) is India’s dominant integrated airport food & beverage operator, founded in 2007 and listed on NSE and BSE in August 2025. The company operates at the intersection of two powerful structural trends: India’s aviation boom and the premiumisation of the travel experience. TFS’s core proposition is simple but extraordinarily powerful — it operates the food courts, branded QSR outlets, and premium lounges that every passenger encounters from the moment they enter an airport terminal to the moment they board their flight.

Travel Food Services (TFS) is the structural beneficiary of India's aviation supercycle. With 26% market share in airport QSR and 45% in premium lounges both commanding positions at 13 of India's top 15 airports TFS functions as a near-monopoly in a captive, premium-spending environment. The business model is extraordinary: a deeply negative cash conversion cycle of -427 days means customers (via card lounge access) and airport operators essentially pre-fund operations, creating a structural float of approximately ₹1,975 Cr. As India's air passenger traffic is projected to grow at a ~9% CAGR to 636 million by FY29, and with 70+ new outlets under construction at upcoming Navi Mumbai and Noida airports, the runway for compounding is substantial.

Read more

Key peers

Read more

Peter Lynch, who coined the idea in One Up on Wall Street and spent most of Beating the Street refining it, would wince. The mall walk, the test drive, the dinner at the new restaurant — these were the first page of his research process. People treat them as the last.

Beating the Street is half memoir of Lynch’s thirteen years running Fidelity Magellan, where he compounded capital at roughly 29% a year and turned a sleepy fund into the largest in the world. The other half is a manual: how to think about stocks if you are not paid to think about stocks for a living. The book is over thirty years old now. Some of it has aged into wisdom; some has aged into wallpaper. Both halves are worth understanding before you quote him at a dinner party.

The original sin in “invest in what you know”

What Lynch actually argued was something narrower than the slogan suggests. His claim was that an alert person — a nurse, a plumber, a mall manager, a teacher — often spots a great company several years before Wall Street does. The doctor who notices a new device transforming surgical outcomes, the regional manager who watches one supplier eat a market, the parent who sees their kids buy three colours of the same toy.

That edge is real. The catch — and it’s the entire catch — is that spotting is not owning. Lynch’s process after the spot was unromantic: pull the annual report. Read the footnotes. Compute the price-to-earnings ratio. Compare it against the growth rate. Look at debt. Understand who the competitors are. Try to talk to the company. Decide which of his six stock categories the business belongs to. Then ask whether the market already knew everything he knew.

Almost nobody does this. The slogan got reduced to “buy the brands you like,” and an entire generation of retail investors believed they had the master’s permission to skip the homework.

The most poignant evidence sits at the back of Beating the Street itself. Lynch tells the story of a class of seventh graders at St. Agnes School in Massachusetts, who built a model portfolio that beat the S&P 500 over two years. The internet still trots out this story as proof that even children can pick stocks. What gets left out is that the kids did written research reports on every holding. They had a teacher who insisted on a clear story for each pick. They had no career risk and no mortgage. They were, in other words, doing the homework most adults skip while invoking their name.

Lynch’s idea was never that ordinary observation is enough. It was that ordinary observation, combined with a few hours of unglamorous reading, is plenty — because the average institutional analyst is too busy modelling next quarter’s earnings to look up from their screen.

What Lynch got right, and is still right about

Set the slogan aside. The book has at least four ideas that have aged remarkably well, and one or two that may matter even more in 2026 than they did in 1993.

The two-minute story. Lynch insisted that for every stock you own, you should be able to explain — in roughly two minutes, in plain language — what the company does, why you own it, what would have to happen for it to make money for you, and what would tell you that you are wrong. If you cannot do this, you do not own a thesis; you own a ticker. Most retail portfolios fail this test on the first stock.

The six categories. Lynch refused to think about all stocks the same way. A slow grower (utilities), a stalwart (a Coca-Cola or HUL), a cyclical (a steel company), a fast grower (a young consumer brand), a turnaround (a wounded company that may heal), and an asset play (a holding company trading below the value of what it owns) all demand different questions, different time horizons, and different reasons to sell. Treating a cyclical like a stalwart is how investors lose money for ten years and then declare the market irrational.

The macro is mostly noise. Lynch’s contempt for economic forecasting is healthy and contagious. He thought the average investor would be better off ignoring interest-rate predictions and unemployment numbers entirely and spending that time reading one extra annual report. Three decades of academic data on macro forecasting accuracy has, gently, agreed with him.

Boring is beautiful. A company with a tedious name, in an unfashionable industry, doing something so dull that the average analyst will not cover it, can be a wonderful place to find mispriced assets. Garbage hauling, fastener distribution, niche packaging — Lynch found tenbaggers in places no Goldman analyst would risk their reputation visiting.

Diversification is not safety past a point. Lynch’s word for it was diworsification — the tendency of investors (and managers) to keep adding holdings until they have so many that no individual win can move the needle. Twenty-five well-understood positions are far safer than seventy half-understood ones, even if a textbook says otherwise.

Where I would be careful

Now the honest part. Three things in Beating the Street should be read with one eyebrow raised.

The first is the survivorship problem. Lynch’s record at Magellan is one of the most extraordinary in the history of public funds. It is also a sample size of one. Many people who tried to imitate his approach in the 1990s and 2000s ended up underperforming the index, sometimes badly. The book reads as if anyone who follows the rules will do well. The data, including Fidelity’s own subsequent performance after Lynch left, suggests that the structural advantages he had — a small fund early on, a still-inefficient market, an army of in-house analysts, and his own particular gift for synthesis — were doing more work than the rules alone.

The second is the dated industry advice. Two whole sections of the book are dedicated to S&L thrifts and to mall-anchor stocks. Both went on to suffer brutal collapses (the 2008 crisis flattened the thrift sector; the slow death of the American mall has been a generational story). Lynch was right about those companies in those years. He was not making a permanent claim about those industries, and readers should not borrow his enthusiasm for their own time.

The third, and most uncomfortable, is the rise of indexing. Since Beating the Street was published, decades of evidence — most associated with Jack Bogle and Eugene Fama — have shown that the great majority of active managers, including very good ones, fail to beat the market net of fees over long periods. Lynch’s book is not wrong about this; he openly says most fund managers do not earn their keep. But he assumes the alternative is a smart amateur picking stocks. The honest alternative for most people, today, is buying a low-cost index fund and going for a walk. Anyone reading Lynch in 2026 should hold both ideas at once: yes, you can beat the market with research and patience; no, the base rate says you probably won’t.

What this means in real life

If you are an ordinary investor reading Lynch for the first time, here are the actionable bits worth keeping.

Do the two-minute test on every stock you currently own. Not in your head — out loud, to a friend who is not in finance. If you stumble, sell.

Categorise before you analyse. Decide which of Lynch’s six buckets the company belongs to. The questions you ask a fast grower (can revenue keep compounding?) are not the questions you ask a cyclical (where are we in the cycle?) or an asset play (what’s it really worth in pieces?).

Use observation as the first filter, not the last. If your daughter loves a new app, that is a hypothesis, not an investment. The work begins after the hypothesis.

Concentrate where you have an edge; index where you don’t. Most professionals run too many positions. Most retail investors own too few quality ones and too many lottery tickets. Lynch’s portfolio had thousands of names because he had a hundred analysts; you do not. Ten to fifteen carefully chosen positions, plus an index fund for the things you don’t understand, is closer to the spirit of his book than a brokerage account full of “stocks I heard about.”

Ignore the macro talk. Spend that time on annual reports and conference call transcripts.

Be honest about your edge. If you cannot articulate, in one sentence, why you know more about this company than the market does, you do not have an edge — you have an opinion.

The closing case

Peter Lynch is one of the few investors whose record almost demands that you read him. But he is also one of the most misread. The damage done by the half-quoted “invest in what you know” — the pile of retail portfolios stuffed with brands their owners liked but never analysed — is probably larger than any individual benefit the line ever produced.

Read Beating the Street the way Lynch wrote it: as a book about work. The mall walk is a hint. The annual report is the job. The two-minute story is the test. If you cannot stomach the work, do not borrow the slogan; buy the index, and use the time saved on something you actually love.

Inventurus Knowledge Solutions Limited operating under the brand IKS Health is a technology-enabled healthcare services company incorporated in 2006 and headquartered in Navi Mumbai, India. The company listed on the NSE and BSE on December 19, 2024, via a 100% offer-for-sale IPO at a price band of Rs 1,265–1,329 per share, with no fresh issue component. The business model is built around a Care Enablement Platform that takes on the administrative, clinical, and financial burdens of US physician enterprises, allowing clinicians to focus on patient care rather than paperwork.

The company serves two primary care settings: outpatient (physician groups, multi-specialty medical groups, academic medical centers) and inpatient (health systems, integrated delivery networks, large hospital complexes). The October 2023 acquisition of AQuity Holdings for approximately $220 million (Rs ~1,800 Cr) was transformative AQuity had historically specialized in inpatient clinical documentation and medical coding, while IKS’s core strength lay in outpatient revenue cycle and clinical documentation. Together, the combined entity now supports approximately 155,000 physicians, or roughly 18% of all practicing physicians in the United States.

Read more

And yet Dilbert ran in over two thousand newspapers, made him wealthy, and turned him into the kind of cartoonist whose absence from the comics page would be noticed in fifty languages. How?

His answer, buried in the middle of How to Fail at Almost Everything and Still Win Big, is the most interesting idea in the book. He calls it the talent stack: a set of ordinary skills that, combined, become extraordinary. Most people chase mastery in one thing. He argues you should quietly accumulate competence in five or six things that fit together — and let the combination do the work.

It sounds modest. It is not. Once you start looking at the world through this lens, a lot of careers, companies, and even relationships start to make uncomfortable sense.

The math of being merely good

Imagine the population of people who are in the top 25% at any single skill — say, public speaking. That is one in four people. Not rare.

Now ask: how many people are in the top 25% at public speaking and writing and basic statistics and one technical domain and knowing how to run a meeting?

If those skills were independent — which roughly, for most people, they are — that is one in 1,024.

You did not become a master of any of them. You just stopped being terrible. But the combination of “merely good at five complementary things” puts you in territory that most specialists never enter, because specialists are busy going from the 95th to the 99th percentile in one place. The marginal returns there are brutal. The marginal returns on adding a fifth complementary skill, starting from zero, are absurd.

This is the engine behind a lot of careers that look like luck from the outside. The product manager who is mediocre at design, mediocre at writing SQL, mediocre at running a workshop, and mediocre at internal politics will eat the lunch of a brilliant designer who can do nothing else. The doctor who can also write clearly will own the public conversation in their field. The engineer who can present without putting a room to sleep will be running it inside a decade.

Adams’s own stack: drawing (acceptable), humour (above average), corporate life (lived through it), persuasion (studied obsessively), and the willingness to publish daily (rare). Take any one away and Dilbert never happens.

Why this is unfashionable advice

Modern career advice is allergic to “be okay at things.” We celebrate obsession, deep work, the ten-thousand-hour myth. We tell young people to “find their thing.” Schools, accelerators, Twitter — all of them reward the specialist’s narrative because it is cleaner.

The talent stack is messier. It says: pick up a second language even though you may never be fluent. Learn enough accounting to read a balance sheet, even though you will never be a CFO. Take the public speaking class. Learn the basics of design. Get conversational at one statistical method. None of it will make you famous on its own. That is the point.

Adams gives a working list of skills he thinks compound for almost anyone: public speaking, business writing, basic psychology, accounting, design fundamentals, conversation, overcoming shyness, a second language, persuasion, and proper grammar. The list is unromantic. There is no “learn to code” or “build a personal brand.” It reads like the curriculum of a half-decent 1950s liberal arts college, which is roughly what it is. That is also probably why it works.

Where the book is right

A few of Adams’s claims have aged remarkably well, and deserve to be lifted out from the rest:

Systems beat goals. A goal is a binary you fail at every day until you don’t. A system is something you succeed at every time you do it. “Lose 20 pounds in six months” is a goal you fail to meet for 179 days. “Walk for 40 minutes each morning” is a system you can win today, and again tomorrow. The energetic difference compounds. He was making this argument in 2013, before Atomic Habits made it conventional wisdom.

Manage energy, not time. Adams insists that the highest-leverage decision you make every day is whatever protects your personal energy — sleep, food, exercise, the order in which you do creative versus administrative work. The book’s odd-seeming dietary detours and “get up at 4 a.m.” anecdotes are all in service of this. You don’t need to follow his exact regimen; you do need to take seriously that being tired makes you a worse version of yourself at every other thing in your life.

Failure as tuition. He failed at restaurants, at corporate climbing, at multiple side projects, at a tech startup. Each one paid him in information. The frame is not “fail fast” — it is “fail with a notebook.” A failure that did not teach you anything is the only kind that is wasted.

Quantity of skills, not quality. This is the talent stack restated. It deserves its own line because it inverts most of what ambitious people are told.

Where I would be careful

Now, the honest part. Adams overreaches in three places.

The first is affirmations. The book leans heavily on the idea that writing or repeating a goal in a specific way somehow bends reality toward it. He attributes large chunks of his own success to this practice. He also attributes his recovery from spasmodic dysphonia — a real and serious neurological condition — to a kind of mental rewiring. These are extraordinary claims, and the evidence is a sample size of one (himself). I am not willing to dismiss it; the placebo effect is real and the mind-body interface is genuinely strange. But “I did X and then good things happened” is the oldest cognitive bias in the book, and Adams, of all people, should know it.

The second is the diet chapter, which is broadly fine but reads now like a 2013 men’s-magazine column. Some of it (eat less white starch, prefer real food, watch your blood sugar) holds up. Some of it is just personal preference dressed as universal truth. Treat it as a prompt to think about your own energy, not as a meal plan.

The third is the persuasion frame that runs through the book and dominates Adams’s later writing. Adams genuinely understands persuasion as a craft, and his observations are useful. But there is a thin line between “understanding persuasion so you are not a victim of it” and “treating every conversation as a thing to be steered.” He sometimes drifts across that line. Read this part of the book with one eyebrow up.

What this means in real life

If the talent stack is the central insight, the practical question is: how do you build one without it becoming a pile of unfinished hobbies?

A few rules I would offer, drawn from the book and from watching it play out in actual careers:

Pick complementary, not random. A second language is good. A second language plus knowledge of one foreign country’s business culture plus the relevant industry vocabulary is a stack. Stamp-collecting skills don’t compound; they cost time and pay nothing back.

Aim for top 25%, not top 5%. Going from competent to elite in any single skill takes years. Going from zero to competent takes weeks or months. Until you have a stack of five competencies, do not try to push any one to elite.

Bias toward skills that produce visible artefacts. Writing produces emails and documents. Speaking produces talks. Design produces decks. These are the skills others see and hire you for. Skills that live only inside your head — even excellent ones — compound much slower.

Add one skill a year. Not five. The point is not to be busy; it is to be cumulative. A decade of one new skill a year is more than most people manage in a lifetime.

Notice your stack already exists. Most readers of this post are already mediocre at four or five useful things and have never thought of them as a portfolio. Inventory them. The next move is usually to add the one missing piece that makes the rest twice as valuable, not to start over.

The closing case

The reason the talent stack matters is that it is one of the few honest answers to the question of how ordinary people end up doing extraordinary things. It does not require you to be a genius. It does not require a lucky break. It does not require you to find your “passion,” whatever that is. It requires patience and a slightly contrarian willingness to keep being a beginner at something, every year, for the rest of your working life.

Adams’s book has weaker chapters and stronger ones. Skip the affirmations if you must. Argue with the diet section. Roll your eyes at the bits where he sounds like a self-help guru. But take the talent stack seriously. The single best career advantage available to most people is hiding in the gap between the things they are already pretty good at, waiting for them to stop chasing mastery long enough to notice it.

Let me tell you what happened when I ran it on TD Power Systems last week.

I typed one command. Twelve minutes later, I had an 8-tab, interactive HTML

Complete with a 16-point fraud screen, Porter’s Five Forces, a 3×3 scenario valuation matrix, a DCF sanity check, peer comparisons against WEG Brazil and Andritz Austria, and a Tankrich Quality Score of 65/100 with a detailed breakdown of exactly why.

The report told me the stock at ₹882 is pricing in FY28 earnings at 35–50x. It flagged that the promoter stake had declined 31.6% over three years without clear explanation. It computed that the OCF/PAT ratio had collapsed to 0.23x in FY25. It calculated the incremental ROIC at 29.7% and graded capital allocation an A.

I didn’t write any of that manually. I built a skill that did

The Problem I Was Solving

I’ve spent years building the Tankrich Investment Framework — multiple analytical sheets covering everything from business model quality to fraud detection to scenario valuation. It’s the framework I use for every stock I research seriously.

The problem? Running it properly on one company takes a trained analyst many days. Ratios to compute. Qualitative questions to answer. Competitor pages to fetch. Management commentary to parse. Scenario matrices to build. Charts to draw.

Most retail investors don’t have 3–5 days. Most small advisory firms don’t have a junior analyst to spare. And most people who want to do serious research get halfway through and give up because the process is too exhausting.

So I asked myself: what if the framework itself could run automatically?

What I Built

The Tankrich Stock Analyst is a Claude skill a structured set of instructions that tells Claude exactly how to conduct a full equity research analysis on any NSE/BSE-listed company.

It runs in three sequential passes:

Pass 1 — Data Collection. It fetches financials from multiple sources, runs 6–8 targeted web searches, discovers 2–3 Indian and 2–3 global peers, and computes 19 quantitative metrics from ROIC to Beneish M-Score signals to the Buffett $1 Test.

Pass 2 — Qualitative Analysis. It applies all Tankrich Framework sheets. Every question answered. Every ratio interpreted in context. Porter’s Five Forces with real competitor names. Fraud screen with 16 individual items. Capital allocation scorecard. Moat detection. Value migration classification.

Pass 3 — Report Assembly. It builds a single self-contained HTML file with 8 tabbed sections, 7+ interactive Chart.js charts in a green-and-white editorial theme, and a 3×3 scenario valuation matrix with target prices at two PE ranges. The whole thing opens in any browser and prints to PDF.

The output is 80,000–100,000 characters.

Why This Changes Something

Here’s what I keep coming back to: the bottleneck in investment research was never intelligence. It was time.

Knowing how to analyse a company — understanding what OCF/PAT means, knowing to check if receivables are growing faster than sales, knowing to look at incremental ROIC and not just headline ROE — that knowledge is teachable. The Tankrich framework encodes it.

The bottleneck was the grinding execution work. Pulling numbers. Cross-referencing years. Fetching competitor data. Building the table. Writing the narrative. That work ate hours. It’s why most retail investors don’t do it, why small advisors rely on recycled brokerage research, and why deep fundamental analysis has always been a resource available mainly to institutions.

Now it’s a 12-minute task.

What It Catches That Brokerage Reports Don’t

Brokerage research is optimized for different things than yours and my interests suggest. Target prices are often anchored to recent momentum. Risks are listed but not seriously weighted. Governance issues are politely mentioned then forgotten.

The Tankrich Analyst doesn’t have those incentives.

On TD Power Systems, it flagged the promoter stake decline of 31.6% over three years — a data point that was publicly available but that I hadn’t seen prominently highlighted in any brokerage note on the stock. It computed that the FY25 OCF/PAT of 0.23x was the weakest in five years and built an explicit monitoring threshold: if OCF/PAT stays below 0.5x for three consecutive years, the earnings quality thesis breaks.

It also told me the company’s asset-based floor value is just ₹21 per share — 2.4% of the ₹882 CMP. Meaning the entire investment is a bet on sustained future earnings, with zero balance sheet protection. That’s not a reason not to invest. But it’s a fact every investor should know going in.

Brokerage research rarely says that as plainly.

Who Should Use This

• If you’re a SEBI-registered RIA managing client portfolios without a full research team, this gives you institutional-depth coverage on any stock, on demand, in minutes — with your own analytical framework stamped on it.

• If you run a PMS or family office, this becomes your first-pass research engine. Your analysts stop spending days pulling together raw data and start spending their time on the 20% that actually requires human judgment — management calls, reading between the lines, forming a conviction view.

• If you’re an independent analyst or financial content creator, this is the difference between covering 5 stocks a month and covering 25.

• If you’re a serious retail investor who has always wanted to do real fundamental research but found it too time-consuming — this is what you’ve been waiting for.

What It Doesn’t Do

I want to be honest about the limits, because hype without honesty is how trust gets destroyed.

The skill works from publicly available data. It cannot replace a conversation with management. It cannot attend an investor day. It cannot pick up on the tone of a CFO’s voice when they answer a question about receivables. It cannot read unpublished supply-chain data or channel-check distributors.

It produces the 80% of analysis that’s based on structured data and systematic frameworks. The remaining 20% — primary research, qualitative judgment, edge from information asymmetry — that’s still on you.

Think of it as the most thorough, most consistent research associate you’ve ever had. One who never gets tired, never skips a step, and applies the same rigour to the 47th company as to the 1st.

Also it is unlikely to work on banks and financial services business

A Note on the Framework Itself

The Tankrich Investment Framework didn’t happen overnight. It’s the accumulated product of years of reading Buffett letters, Charlie Munger’s mental models, Michael Porter’s competitive strategy work, the writings of practitioners who’ve actually managed money across market cycles.

The sheets encode specific things I’ve learned matter: that incremental ROIC is a better management quality signal than headline ROE, that fraud detection requires looking at 16 specific items not just “governance,” that valuation without a scenario matrix is just guessing, that the Earning Power Box tells you something about a business’s quality that no single ratio can.

Encoding that framework into a skill means it gets applied consistently. No shortcuts. No “I’ll skip the cash flow analysis because the margins look great.” Every company gets the full treatment, every time.

The Bigger Picture

We’re at an inflection point in financial analysis. The tools that were previously only available to analysts at top-tier funds systematic frameworks, global data access, rapid synthesis are now available to anyone willing to build with them

The Tankrich Stock Analyst is my attempt to make sure the leveling up is accessible.

On 22 April 2026, Cochlear (COH.AX) delivered one of the most savage single-day sell-offs in its 30+ years as a listed company. Shares opened down 32% and closed the session ~40% lower, wiping out more than A$4.4 billion in market value in a single trading day. A decade low and 64% below its 52-week high of $319.56.

Read more

Read more

Preface: Why This Business Earns the Right to Be Studied

Charlie Munger once said that all he wants to know is where he is going to die so he never goes there. Applying that inversion to equity investing: I want to know what kinds of businesses destroy wealth, so I can look for the opposite. Businesses that destroy wealth are typically commoditised, face powerful buyers and suppliers, operate in shrinking markets, have undisciplined management, and burn more cash than they generate. MTAR Technologies is, in almost every meaningful dimension, the opposite of that archetype.

MTAR makes precision-engineered components parts that hold tolerances of five to ten microns for four customers who cannot easily switch to anyone else: the Department of Atomic Energy (nuclear power), ISRO (space and launch vehicles), the Ministry of Defence (missiles and fighter aircraft), and Bloom Energy (solid oxide fuel cells for AI data centres). Each of these relationships is decades old. Each is protected by a qualification process that takes seven to ten years and cannot be shortcut. Each segment is, independently, in the early innings of a long structural growth story.

This post is my attempt to rigorously apply an integrated analytical framework business quality, competitive advantage, management integrity, financial health, and valuation to arrive at an honest assessment of what MTAR is worth and whether the current price offers a margin of safety. I will try, in the tradition of good research, to argue both sides of the trade honestly before arriving at a conclusion.

Personal Research. Not Investment Advice. I have may or may not have position in the stock and I am not going to provide to any regular update on this company , use this post as starting point and not as a stock tip.

Part I: The Business — What Does MTAR Actually Do?

1.1 The Irreplaceable Component Maker

MTAR Technologies, headquartered in Hyderabad and founded in 1970 by P. Ravindra Reddy, is a precision engineering company that manufactures components and sub-assemblies for mission-critical applications. The key word is “mission-critical.” When the Vikas engine powers a PSLV rocket off the launchpad, or when a nuclear reactor at Kaiga runs its drive mechanisms, or when a Bloom Energy fuel cell quietly generates power for an Amazon data centre somewhere in that chain is a component made by MTAR.

The company’s business can be described simply: take a block of exotic alloy (Inconel, titanium, nuclear-grade steel), and machine it to tolerances that most manufacturing facilities in the world cannot achieve. Then deliver it on time, with the precise documentation trail that nuclear regulators, ISRO quality assurance, and US defence contracts demand. That is the whole business. Simple to describe. Extraordinarily difficult to replicate.

1.2 The Four Business Segments

MTAR’s revenues come from four distinct segments, each with its own demand driver, customer relationship, and growth trajectory:

A critical observation: each of these four segments has an independent demand driver. If India’s nuclear programme slows, Bloom Energy’s data centre orders might be accelerating. If ISRO delays a launch, the defence ministry might be awarding more missile contracts. This multi-segment structure provides meaningful earnings resilience that a single-customer precision manufacturer would not have even as the Bloom Energy concentration (55% of FY25 revenue) remains the single most important risk to monitor.

Part II: The Industry — Four Secular Growth Vectors

2.1 Clean Energy: The AI Data Centre Tailwind

Bloom Energy makes solid oxide fuel cells (SOFCs) devices that convert natural gas into electricity at approximately 60% efficiency without combustion, generating very little noise, zero water usage, and dramatically lower emissions than diesel generators. For AI data centres, which require 24/7 uninterrupted power at densities that the conventional grid struggles to supply, SOFCs are increasingly the answer.

In FY2025, Bloom Energy reported record revenues of $2.02 billion, up 37.3% year-on-year. For FY2026, management has guided revenues of $3.1–3.3 billion —> implying 54–63% growth. The company’s product backlog has surged to approximately $20 billion. The AI data centre boom is the primary driver.

MTAR’s current hot box capacity is 8,000 units per year. The company is investing to expand this to 12,000 units (FY26), 20,000 units (FY27), and 30,000 units (FY28). This phased expansion demand-driven, backed by signed supply commitments is the most visible near-term earnings catalyst for MTAR. In September 2025, MTAR secured a $43.9 million supply deal with Bloom Energy for hot boxes and electrolyzer units, confirming the trajectory.

2.2 Nuclear Power: India’s Renaissance

India currently has approximately 8,200 MW of nuclear power capacity across 24 reactors. The government has approved 13 new reactors including ten 700 MW Pressurised Heavy Water Reactors (PHWRs) targeting 21,880 MW by 2032. Three units are under construction (RAPS-8, GHAVP-1, GHAVP-2). The ASHVINI joint venture between NPCIL and NTPC adds four more 700 MW units at Mahi Banswara. By 2047, India targets 100 GW of nuclear capacity.

For a precision component manufacturer with MTAR’s nuclear qualifications, this is multi-decade locked-in revenue. Nuclear reactor construction requires thousands of precision-machined components, each with specific material certifications, dimensional tolerances, and quality documentation trails that take years to establish. MTAR’s Q3 FY26 nuclear order inflows of ₹500 crore in a single quarter signal the acceleration of this opportunity.

The moat in nuclear is perhaps the deepest of all four segments. India’s nuclear regulatory framework (the Atomic Energy Act, 1962, and the Atomic Energy Regulatory Board) requires that every supplier to a nuclear facility maintain an approved quality assurance manual, complete material traceability, and a physical inspection and test record for every component. Getting “qualified” as a nuclear component supplier takes seven to ten years. Once qualified, there is effectively no price competition NPCIL cannot simply switch to a cheaper supplier without repeating the entire qualification process.

2.3 Defence: India’s Atmanirbhar Imperative

India’s defence budget for FY2026–27 stands at ₹7.85 trillion a fifteen percent increase year-on-year and an all-time high. More importantly for MTAR, seventy-five percent of the total acquisition budget is now earmarked for domestic procurement, up from fifty-eight percent in FY20-21. The government’s stated target is to double military production to ₹3 trillion by 2029.

MTAR’s defence relationships are deep and long-standing. The company supplies precision assemblies for the Agni missile programme, has partnered with Adani Defence for the Advanced Medium Combat Aircraft (AMCA) prototype, and holds AS9100D and CEMILAC certifications that are prerequisites for defence supply. Defence capex is projected to grow at 12.3% CAGR through 2030 faster than overall defence spending (7.8% CAGR) as India accelerates indigenous military hardware production.

2.4 Space: The Gaganyaan Era

India’s space policy, revised in 2023, opened the sector to private participation for the first time. The Indian space economy currently approximately $9 billion is projected to reach $44 billion by 2033, implying a 26% CAGR. MTAR has been ISRO’s trusted supplier of propulsion system components since 1983, a relationship spanning the company’s entire modern history.

Gaganyaan, India’s crewed spaceflight programme, is in final stages. The first uncrewed test mission (with the Vyommitra half-humanoid robot) is scheduled for early 2026; the crewed mission has been moved to Q1 2027. ISRO’s semi-cryogenic engine, which will boost LVM3’s payload capacity by 24% while reducing costs by 25%, is scheduled for its first flight in 2027. MTAR is the manufacturer of choice for both programmes. Each new launch vehicle variant, each new mission, requires a new set of precision engine components and MTAR is the supplier.

Part III: The Moat — Why Can’t a Competitor Do This?

3.1 Porter’s Five Forces: An Unusually Favourable Structure

I find it useful to run a business through Porter’s Five Forces before reaching any conclusion about competitive advantage. For MTAR, the exercise produces a striking result.

Entry barriers are extraordinarily high. To supply nuclear reactor components, a new entrant must spend seven to ten years obtaining nuclear quality assurance certifications, building the institutional knowledge to maintain them, and convincing a government regulator who is accountable for the safety of millions of people to approve them as a supplier. No private equity investor would fund a start-up to displace MTAR in the NPCIL supply chain. The economic incentive does not exist, because NPCIL would not approve the switch.

Buyer power is near zero in three of four segments. NPCIL cannot switch suppliers without a multi-year re-qualification. ISRO cannot rebuild a 43-year supplier relationship overnight. Bloom Energy has invested capital in MTAR’s capacity expansion they are financially committed to the relationship. Only in defence, where HAL and DRDO have some alternatives, does buyer power exist at a moderate level.

Supplier power is moderate but manageable. MTAR uses specialty alloys (Inconel, titanium, nuclear-grade steel) from a limited number of approved global suppliers. However, the company’s vertical integration in-house heat treatment, coating, assembly, and inspection reduces its dependency on any single input supplier. The machines themselves (DMG Mori, Makino CNC centres) are capital items, not recurring inputs.

Competitive rivalry is effectively zero within MTAR’s specific niches. There is no Indian competitor qualified to supply NPCIL’s fuel machining heads. There is no alternative supplier of hot boxes for Bloom Energy from India. The company is not competing in a market; it is operating in a series of captive niches where it is the only qualified incumbent.

Substitute products present negligible risk. A nuclear reactor’s drive mechanism cannot be substituted. An ISRO Vikas engine’s turbopump casing has no alternative design. The precision of the end application mandates the precision of the component.

3.2 Sources of Competitive Advantage

Scouring the literature on competitive advantage Porter, Buffett, Munger, Pat Dorsey I find MTAR has not one but four overlapping sources of moat, which is the hallmark of a truly durable franchise:

1. Regulatory and certification moat

• Nuclear N-stamp equivalent (NPCIL QAM), ISRO AS9100D, DRDO/CEMILAC approvals, and Bloom Energy’s proprietary supplier qualification. These are not certificates that can be bought or rushed. They are earned through years of zero-defect delivery, detailed documentation, and site audits. Replication by a new entrant is possible in theory and near-impossible in practice.

2. Customer lock-in moat

• The switching cost for MTAR’s customers is asymmetric. For NPCIL, switching costs are effectively infinite the regulatory re-qualification process would take longer than the component’s own service life. For Bloom Energy, switching costs include the capital it has co-invested in MTAR’s capacity expansion. Switching costs create pricing power, and pricing power is the core of long-term value creation.

3. Process know-how moat

• Five-to-ten micron tolerances at production scale is not a specification that can be achieved by purchasing new CNC machines. It requires accumulated process knowledge: the right coolants, tool paths, fixturing methods, inspection protocols, and crucially, a workforce that has internalized these methods over years. MTAR’s Hyderabad facility has engineers who have been machining these components for two and three decades.

4. Institutional relationship moat

• MTAR’s relationship with ISRO predates the company’s own stock market listing by three decades. The institutional memory the tacit knowledge of what ISRO needs, how it reviews drawings, what its quality assurance culture demands lives inside MTAR. Bloom Energy’s engineers have worked alongside MTAR’s manufacturing team to co-develop the hot box production process. These relationships are not assets on the balance sheet, but they are the most valuable thing the company owns.

“A truly great business must have an enduring moat that protects excellent returns on invested capital. The dynamics of capitalism guarantee that competitors will repeatedly assault any business castle that is earning high returns.” — Warren Buffett, 2007 Annual Letter

The question for MTAR is not whether the moat exists it clearly does but whether it is wide enough to sustain returns on capital above the cost of capital over a long period. The answer is yes, with the important caveat that current reported returns are temporarily depressed by the profit compression of FY24–25. I will address this in detail in next part

Part IV: The Management — The Stewards of the Fortress

4.1 Capital Allocation: The Ultimate Test

Munger says the most important quality in a CEO is rational capital allocation. Let us apply that test to MTAR.

The company has, over the past three years, invested approximately ₹300 crore in expanding its hot box manufacturing capacity and nuclear component production lines. This capex is demand-led: signed supply contracts from Bloom Energy and confirmed NPCIL orders preceded the capacity expansion. It is the unglamorous, patient work of building capacity ahead of confirmed demand.

The IPO proceeds in FY21 (₹600 crore raised) were used for debt repayment and working capital, consistent with the stated use of proceeds. There have been no acquisitions at dubious valuations, no related-party transactions of concern, and no issuance of warrants to promoters at below-market prices.

Where capital allocation has been imperfect is in working capital management. Inventory days swelled from 82 in FY19 to a peak of 246 in FY23, and remained elevated at 186 in FY25. Management attributed this to pre-stocking for anticipated large orders from Bloom Energy and NPCIL orders that were then deferred, creating a cash conversion headache. The vindication of this explanation came in Q3 FY26, when record revenues of ₹278 crore the quarter in which the pre-stocked inventory was finally shipped resulted in OCF of approximately ₹102 crore for the full FY25 (1.89 times net profit).

4.2 The Fraud Screen: Applying the Checklist

I run every management through a standard fraud and governance checklist. For MTAR, the results are largely reassuring:

4.3 The Promoter Selling Question: The One Genuine Concern

Promoter holding in MTAR fell from 36.4% to 31.4% in a single quarter September to December 2024. This is the single most important governance concern I have with the company. Let me think through it carefully.

There are two interpretations. The pessimistic interpretation: the founders have concluded that the stock is overvalued at these prices and are reducing their stake while they can. This would be consistent with the behaviour of insiders who know something the market does not.

The optimistic interpretation: second-generation promoters are diversifying personal wealth a rational and common behaviour in Indian family-run companies, especially post-IPO when shares become liquid for the first time. The timing (high stock price) is rational personal finance, not necessarily a statement about the business.

My honest assessment: I cannot determine which interpretation is correct from the available information. What I can say is that total promoter holding of 31.4% is meaningfully lower than the 46%+ post-IPO level, and the pace of reduction is faster than I would like. I watch this metric quarterly. A fall below 28% would cause me to revisit the thesis with renewed scepticism.

4.4 Second Generation: The Succession Question

The current MD, Parvat Srinivas Reddy, is the second generation. The institutional relationships with ISRO, NPCIL, DRDO, and Bloom Energy were established by his father, P. Ravindra Reddy, over fifty-plus years. How much of the relationship is personal versus institutional?

The answer, I believe, is mostly institutional. ISRO’s procurement process does not depend on knowing the founder personally; it depends on supplier qualifications, drawing approvals, and quality records. NPCIL’s nuclear quality assurance programme is a bureaucratic institutional process, not a personal one. Bloom Energy’s manufacturing partnership is governed by supply contracts, not personal relationships. The risk of relationship loss due to succession is real but, in my assessment, manageable.

Part V: The Financials

5.1 The Business Model Ratios: Applying the Framework

The most important financial question for any business is: does it earn returns above its cost of capital? For MTAR, the answer requires careful interpretation. The company’s “normal” earnings are not represented by FY24 or FY25 both of which were distorted by order deferrals, interest cost from growth capex, and elevated inventory. The “normal” earnings are better represented by FY23 (₹104 crore PAT) or the FY27 recovery scenario.

Two observations from this table demand our attention.

First, the RONW-versus-WACC comparison. In FY25, MTAR’s return on equity of 7.4% is below its estimated WACC of 12%. This means the company, at current reported earnings, is not creating economic value it is consuming it. This is a critical finding that a bullish investor cannot ignore. The counter-argument is that current earnings are cyclically depressed by three factors: (a) elevated depreciation from the FY22–24 capex cycle, (b) interest costs on the debt taken on to fund that capex, and (c) the one-time working capital impact of pre-stocking for orders that were deferred. At normalised FY27 earnings which I will estimate in Part VII RONW recovers to approximately 15–17%, consistent with the FY19 and FY23 peaks.

Second, the OCF-to-PAT ratio. After years of sub-optimal cash conversion (FY21–24), FY25 delivered OCF of ₹101.8 crore against PAT of ₹53.9 crore a ratio of 1.89 times. This is powerful evidence that the underlying business generates real cash. The high depreciation (non-cash charge of ₹31.8 crore in FY25) is the primary driver of this divergence. A business that generates ₹102 crore of operating cash on ₹676 crore of revenue is a healthy business, even if the reported profit line looks compressed.

5.2 Revenue: Quality and Consistency

MTAR’s revenue has compounded at 26.5% per annum over ten years, it reflects genuine secular demand from all four end-markets, the company’s successful qualification for new programmes (Bloom Energy’s hot box, nuclear PHWR series), and its expanding share of ISRO’s propulsion component budget.

FY24 was the one stumble revenue growth of just 1.2%. I have analysed this carefully. It was order deferral: Bloom Energy pushed shipments from early FY24 into late FY24 and FY25, partly due to their own inventory management and partly due to data centre project timing. NPCIL similarly pushed some nuclear component orders due to construction scheduling. Neither deferral was a structural deterioration of the business relationship. The proof is in Q3 FY26: record quarterly revenue of ₹278 crore, fresh orders of ₹1,369 crore in a single quarter, and an order book of ₹2,395 crore representing 3.5 times annual revenue.

5.3 Accounting Quality: A Clean Bill of Health

I have run MTAR through a detailed accounting quality screen and found no meaningful red flags. Revenue recognition is conservative: orders are confirmed, manufactured, inspected, delivered, and then recognised. There are no aggressive policy changes, no unusual reserves, no repeated restructuring charges. The auditor is KPMG’s BSR & Co. a Big 4 firm with appropriate independence and credibility. Tax rates at approximately 26% are consistent with statutory rates. There are no FCCB liabilities, no material derivative exposure, and no off-balance-sheet obligations of concern.

The one accounting observation worth noting is the inventory build. Inventory as a percentage of revenues has risen from 22% in FY19 to 51% in FY23 and stands at 51% in FY25. Management’s explanation that this represents pre-stocking for anticipated large orders has been validated by Q3 FY26’s record delivery. But working capital efficiency remains a key metric to track: the target of reducing inventory days from 186 to 140–160 by FY27 will be the financial test of management execution.

Part VI: The Risks — Invert, Always Invert

6.1 The Inversion Discipline

Rather than asking what must go right for this investment to work, let us ask what must go wrong for it to fail. If we can identify the failure conditions clearly, we can then assess their probability and decide whether the current price adequately compensates us for those risks.

6.2 Risk 1: The Bloom Energy Concentration

Bloom Energy accounts for approximately 55% of MTAR’s FY25 revenue. This is the most important risk in the thesis. If Bloom Energy’s demand slows whether because the AI data centre capex cycle moderates, because Bloom loses ground to battery storage or nuclear microreactors, or because Bloom faces financial distress MTAR’s revenue and earnings would be materially impacted.

The mitigating factors: Bloom’s $20 billion backlog and $3.1–3.3 billion FY2026 revenue guidance provide 6–8 years of near-term visibility. MTAR’s supply contract is denominated in USD, providing a natural hedge against INR strength. And MTAR is actively diversifying nuclear now represents 31% of the order book versus 20% of recent revenues, and defence is growing through the AMCA programme.

My assessment: a 30–40% decline in Bloom Energy orders over a 12-month period would reduce MTAR’s FY27 revenue by approximately ₹300–400 crore and push PAT below ₹60 crore. At that PAT level, and at the current market capitalisation, the stock would be deeply unattractive. This is the bear case in Part VII.

6.3 Risk 2: Valuation Demands Execution

At a trailing P/E of 205 times, MTAR is not a stock you own passively. It is a stock that demands quarterly monitoring. At current depressed earnings of ₹54 crore PAT, the entire market capitalisation of ₹11,068 crore implies a payback period of over 200 years on current earnings. This is only sensible if you believe as I do that FY25 earnings are cyclically depressed and will recover sharply.

Any disappointment in the recovery trajectory whether FY26 revenue falls short of the implied 40–50% growth, or margins fail to recover toward 21–23%, or the order book shrinks rather than grows would cause a violent de-rating. The premium valuation is the sword of Damocles hanging over every MTAR position.

6.4 Risk 3: Working Capital and Liquidity

With net debt of ₹161 crore and cash of only ₹16.6 crore, MTAR does not have a large liquidity buffer. If order deferrals were to recur as they did in FY24 the company would face both a revenue shortfall and continued working capital stress. In an extreme scenario, a second year of ₹55–60 crore PAT with continued inventory build would push the balance sheet toward a point where equity dilution becomes a risk.

This risk is mitigated by the strong OCF generation in FY25 (₹102 crore) and the signed nature of the order book ₹2,395 crore of confirmed orders provides meaningful revenue visibility. But liquidity is not abundant, and I factor this into position sizing.

6.5 Risk 4: Promoter Governance

I have discussed this above. The significant promoter stake reduction in one quarter is the most immediate governance concern.

A continuation of this trend specifically a fall below 28% holding would cause me to reassess whether the founders are signalling something about the future that is not yet visible in the order book or earnings.

6.6 Risk 5: Government Programme Delays

Every MTAR revenue segment is ultimately dependent on government programme execution. Gaganyaan has been delayed twice. NPCIL nuclear projects have historically faced construction schedule slippage. DRDO programmes run on bureaucratic timelines that can shift. This structural feature of MTAR’s business means that quarterly earnings will always be lumpy and partially unpredictable. Investors who need smooth, predictable quarterly earnings should look elsewhere.

Part VII: The Valuation — What Are We Paying and What Do We Get?

7.1 The Scenario Framework

I use a three-scenario approach pessimistic, base, and optimistic to bracket the range of reasonable outcomes. The key inputs are FY27 revenue (two years forward from FY25’s ₹676 crore base) and EBITDA margin. I then estimate PAT after subtracting estimated D&A and interest of approximately ₹55 crore and applying a 26% effective tax rate.

The probability-weighted expected price, using these scenarios, is approximately ₹4,100–4,300 — implying 14–19% upside from the current market price of ₹3,598. This is a modest but positive expected return, with the key swing factor being whether Bloom Energy’s FY26 revenue guidance ($3.1–3.3 billion) materialises as expected.

Why 80–100x was used

MTAR is priced as a quality compounder in a structurally scarce category precision engineering for mission-critical, defence-adjacent applications with deep regulatory moats. The Indian market has historically rewarded this category of company with premium multiples. Comparable companies like Mtar’s closest peers (MTAR itself listed at ~85x FY22 earnings), and broader “capital goods with moat” names like Kaynes Technology, Divi’s Laboratories at peak, or Data Patterns have all commanded 60–120x PE during growth phases. The argument for a high multiple rests on:

• Earnings visibility from a ₹2,395 Cr order book (3.5x annual revenue)

• Decade-long customer lock-in that makes earnings more bond-like than typical manufacturing

• Low float + high institutional demand for quality precision engineering names

• The Bloom Energy growth trajectory is essentially contracted, not projected

7.2 The Munger Big-No-Brainer Test

Munger advocates identifying the “big no-brainer” elements of any investment thesis — the irreducible facts that determine the outcome. For MTAR, these are:

• Even in the bear case (₹1,014 crore revenue, 17% EBITDA margin), PAT of ₹87 crore puts the stock at 127 times FY27E earnings at current prices. This is not cheap on any traditional metric.

• In the base case (₹1,278 crore revenue, 20% margins), FY27E PAT of ₹148 crore puts the stock at 75 times forward earnings — expensive, but potentially defensible for a business with structural moats in four of India’s fastest-growing sectors.

• The bull case (₹1,572 crore revenue, 23% margins) requires flawless execution on Bloom’s record backlog, nuclear Kaiga order conversion, and defence AMCA ramp-up — simultaneously. Possible, not certain.

• The downside is asymmetrically worse than a typical quality stock because the current P/E of 205 times leaves no room for any negative surprise. A single quarter of missed expectations would cause a sharp derating.

The math, therefore, favours owning MTAR but not at any price.

7.3 What the Stock Price Already Assumes

A useful discipline before buying any stock is to reverse-engineer what the current price assumes. At ₹3,598 and 3.076 crore shares outstanding, the market capitalisation is ₹11,068 crore. To justify this at a long-run P/E of 60 times (which itself assumes structural competitive advantage), the market is assuming steady-state earnings power of approximately ₹185 crore PAT.

Is ₹185 crore PAT achievable? Yes — it requires approximately ₹1,200–1,300 crore of revenue at 21–22% EBITDA margins. This is the base case FY27E scenario. In other words, the current stock price is essentially already pricing in the base case FY27 outcome. There is limited upside unless the bull case materialises, and meaningful downside if the bear case unfolds.

Part VIII: Conclusion — The Thesis in Full

8.1 What This Business Is

MTAR Technologies is a precision engineering company with irreplaceable positions in four of India’s most structurally attractive growth sectors. It is a fast grower — revenue CAGR of 26.5% over ten years — in a temporary profit dip caused by order timing, not business deterioration. Its competitive advantages — nuclear certifications, ISRO approvals, sole-supplier lock-in with Bloom Energy are the most durable kind: regulatory and relationship-based moats that take a decade to replicate and cannot be purchased.

8.2 What the Numbers Say

The business earns above its cost of capital in normalised years. FY23 ROE of 16.8%, ROA of 12.1%, and EBITDA margins of 26.9% are the benchmark for what this business can achieve. FY24–25 represent a temporary compression, not a structural reset. Q3 FY26’s record revenue and expanding margins confirm the recovery thesis. The order book of ₹2,395 crore provides 3.5 times revenue coverage the highest in the company’s history.

8.3 The Key Monitoring Framework

This is not a stock to own passively. The following metrics must be tracked every quarter:

8.4 The Final Verdict

MTAR Technologies is a high-quality franchise in a temporary earnings dip, operating in four of the most structurally attractive sectors in India’s economy. The competitive advantages are genuine, durable, and difficult to replicate. The management is largely clean with one important governance concern (promoter selling) that requires ongoing monitoring. The accounting is conservative and the OCF generation is strong.

The principal risk is valuation: at 205 times trailing earnings, the stock price has already priced in a substantial recovery. The base case FY27 scenario ₹1,278 crore revenue, 20% EBITDA margin, ₹148 crore PAT implies a forward P/E of approximately 75 times, which leaves limited room for valuation expansion. The margin of safety is thin at the current price.

To use the language of risk-reward: the upside is modest from here, the downside is manageable for a patient investor, and the long-term compounding story if MTAR executes over five to seven years across all four segments is genuinely compelling. The stock belongs in a portfolio of high-quality Indian businesses. The position size should reflect the valuation premium and the Bloom concentration risk.

“The stock market is a device for transferring money from the impatient to the patient.” — Warren Buffett

— End of Thesis —

Now ask yourself: who manages all of this, invisibly, at scale, for 3,200 hospitality and travel clients across 100 countries? The answer, almost certainly unknown to most investors who do not work in the travel industry, is RateGain Travel Technologies.

Read more

Imagine urban India in 2030. A young professional in Bengaluru opens her phone at 8:47 PM and orders dinner, fresh groceries, and two cinema tickets all delivered or confirmed within fifteen minutes, all through a single platform. She does not think about the extraordinary logistics ballet this requires, any more than she thinks about the electrical grid when she flicks on a light. This seamlessness this invisibility is the ultimate aspiration of Eternal Limited, and it is the quality that makes the company worthy of disciplined analytical attention.

We approach this essay from the Buffett-Munger tradition of value investing: patient, first-principles, deeply skeptical of consensus, and relentlessly honest about uncertainty. Munger reminds us that the best way to understand a business is to try, earnestly, to destroy it to find the failure modes before the market does. This is Jacobi’s inversion maxim applied to equity analysis: invert, always invert. Rather than ask “why will Eternal succeed?”, we first ask “under what specific conditions would this investment permanently impair capital?” The answer to that question disciplines everything that follows.

At current prices of ₹230 per share (March 2026), the market is asking investors to pay 959 times trailing earnings and roughly 5 times trailing revenue for a business that earned its first full year of operating profitability only in FY24. That is either extraordinary insight about future earnings power, or extraordinary optimism. This essay attempts, with rigour and intellectual honesty, to determine which

Read more

Smaller pharmaceutical companies and even large ones pursuing asset-light strategies increasingly find it rational to outsource this complexity to specialists who have already made the investment. Akums is that specialist, at scale. The company operates 14 state-of-the-art manufacturing facilities, producing an extraordinary range of 60+ dosage forms: tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, gummies, and nasal sprays. Its cumulative CDMO formulation capacity stands at 49.6 billion units annually.

Akums operates across three revenue segments. First, the CDMO business the core which contributes approximately 78% of group revenue. Here, Akums manufactures formulations for over 1,400 clients, including 26 of the Top 30 Indian pharmaceutical companies by sales. The client relationship is deeply embedded: once a product is qualified at an Akums facility, switching requires regulatory re-filing and re-audit, creating natural stickiness. Second, the branded formulations business, run through subsidiaries Akumentis (India) and Unosource (70+ export countries), which sells Akums’ own branded and generic products. Third, the API (Active Pharmaceutical Ingredients) business, which manufactures key starting materials primarily cephalosporins and is currently loss-making due to price erosion, but strategically positioned as a supply chain hedge.

A defining characteristic of Akums’ position is the breadth of its intellectual property in manufacturing processes. The company has commercialised 4,146 formulations across 60+ dosage forms since inception. This library of manufacturing know-how, built over 20 years, is not easily replicated.

Read more

In the middle of this noise, Raamdeo Agrawal quietly releases the 21st Annual Wealth Creation Study themed “Focused Investing: Power of Allocation in Wealth Creation.”

Most people read the top 10 lists and moved on. A few read the Kelly formula section and found it interesting. Almost nobody internalised the framework deeply enough to act on it.

Nine years later, the companies in that study have gone in wildly different directions.

One became the decade’s biggest fraud. One collapsed from a single newspaper headline. One became a multi-trillion-rupee compounding machine. And some of the companies the study labelled wealth destroyers came back as the best performers of the subsequent five years.

The framework predicted all of it.

This post is my attempt to reconstruct what the 21st Study actually said, audit it honestly against what happened, and then apply its logic to where we are today.

Part 1: The Problem Nobody Talks About

Before getting to the framework, understand why it was even necessary.

In equity investing, virtually all discussion centres on what to buy which sector, which company, which theme. The 21st Study opened with a disarmingly simple observation: the previous 20 annual studies had all been about what to buy. Not one had seriously addressed how much to buy.

This is a massive blind spot.

To illustrate, the study presented a hypothetical portfolio of 10 stocks with varying individual returns: one stock returned +50%, another +40%, down to one that returned -40%. Now, if you invested equally across all 10, your portfolio returned 5%.

But here’s the punchline: the same 10 stocks, simply by changing how much you allocated to each, delivered total portfolio returns ranging from -8.5% to +18.5%.

Same stocks. Same returns on each stock. Wildly different outcomes based purely on allocation.

It is what happens in real portfolios every single day. Most investors who got the stock selection right still underperformed because they sized the wrong bets too large and the right bets too small.

The 21st Study called this the most underresearched aspect of investing, and it set out to fix that.

Part 2: Kelly’s Formula, Decoded

To build their allocation framework, the study borrowed from an unlikely source: John Larry Kelly Jr, a scientist at Bell Labs who, in 1956, developed a mathematical formula for placing optimal bets in games of chance.

Kelly’s original formula: f = (bp – q) ÷ b

Where f is the fraction of your capital to wager, b is the odds (how much you win per rupee bet), p is the probability of winning, and q is the probability of losing.

The study adapted this for equity investing where the outcomes are not binary, losses are rarely total, and both probabilities and payoffs are estimated rather than known. The equity version becomes:

f = (Up – Dq) ÷ U

Where U is the potential upside, D is the potential downside, p is your estimated probability of the upside occurring, and qis your probability of the downside.

The mathematics become secondary. The three insights from Kelly are what matter practically:

Insight 1: Look for asymmetric payoff. The ideal investment situation is one where the upside is large and the downside is small. Not 2:1 odds. Genuinely asymmetric situations where a correct thesis gets you 5x and an incorrect thesis loses you 20–30%. These are not common. But when they appear, the formula says: act.

Insight 2: Create an edge. In Kelly’s framework, you only bet when you have an edge when you know something that tilts the odds in your favour. In equity markets, information advantages have been largely arbitraged away by technology. What remains is analytical advantage: understanding a business or sector more deeply than the consensus. This takes work, not tips.

Insight 3: When you have edge and asymmetry together bet big. This is the counterintuitive one. Most investors diversify by reflex, diluting their best ideas with their weakest ones. Kelly says that when you have genuine conviction supported by genuine analysis, concentration is not recklessness it is optimal. Please read word that again genuine is 2 hours of chat with chatgpt

The study encapsulated this in four words: Bet seldom. Bet big.

Part 3: What Is Focused Investing, Exactly?

The study positioned Focused Investing as the golden mean between two extremes.

Diversified investing (50+ stocks, index investing) is the dominant form of institutional investing. Its virtue is managing volatility. Its vice is that it guarantees average returns you are essentially buying the market’s average.

The US data is telling. A 2012 academic study (Yeung et al.) found that portfolios consisting of only the highest-conviction bets of fund managers their top 5 to 10 positions consistently outperformed the very funds from which those bets were extracted, and did so without significantly higher risk. The managers knew their best ideas. They just buried them in noise.

Concentrated investing (less than 10 stocks) is the style of investors like Warren Buffett, Charlie Munger, and Phil Fisher. Buffett’s alpha over the Dow during his partnership years (1957–1968) was 20.4% per year. Munger’s alpha over S&P 500 was 14.9%. The returns are extraordinary but the year-to-year volatility is psychologically brutal.

Focused Investing the study’s recommended approach is 15 to 20 stocks across sectors. Enough to diversify company-specific risk. Concentrated enough for meaningful allocation in high-conviction ideas. Risk research shows that company-specific risk is near-fully diversified at 15–20 stocks; adding more stocks beyond this point adds no diversification benefit.

In practice, this means: maintain a watchlist of 50–100 quality businesses, have serious conviction on 15–20, and size them based on relative confidence not uniformly.

Part 4: The Selection Filter — QGLP

For stock selection, the study formalised a framework that Raamdeo Agrawal had been practising for two decades: QGLP — Quality, Growth, Longevity, and Price.

Q — Quality of Business × Quality of Management. The study expressed this as a multiplication, not addition. If either is zero, Q is zero. A phenomenal business with fraudulent management? Q = 0. A brilliant manager running a commoditised, structurally declining business? Also Q = 0. Both conditions must be satisfied.

Quality of business is assessed through: competitive moat (monopoly/oligopoly positioning, brand strength, switching costs), large profit pool, pricing power, high and sustained Return on Equity, and strong operating cash flow.

Quality of management is assessed through: unquestionable integrity (governance, tax compliance, dividend policy), demonstrable competence (strategy and execution track record), and growth mindset (capital allocation, long-term orientation).

G — Growth in earnings. The study makes a subtle but crucial point: growth only creates value when a company earns returns above its cost of capital. A company growing revenues at 30% but deploying capital at 8% returns while its cost of capital is 12% is actually destroying value. Growth is an amplifier — it makes good businesses better and bad businesses worse.

L — Longevity of Q and G. This is where most investors underestimate. A business that is high-quality and high-growth today but loses its advantage in 3 years is worth far less than one that sustains both for 15 years. The study introduced the concept of Competitive Advantage Period (CAP) — the duration over which a company generates returns above its cost of capital. Extending CAP is the holy grail of quality investing.

P — Price. No quality framework is complete without a valuation discipline. The study is explicit: even the best company, bought at the wrong price, will disappoint. The simplest test is whether you are getting valuation growth as a tailwind (buying below intrinsic value) or a headwind (buying above).

The selection framework essentially says:

if a company scores high on Q, G, and L — and you can buy it at a P that represents reasonable value allocate meaningfully. If Q is questionable, no price makes it a good investment.

Part 5: The Allocation Tool — CAP (Confidence-Adjusted Payoff)

Having selected stocks using QGLP, the study proposes CAP — Confidence-Adjusted Payoff as the allocation tool.

CAP translates your analytical conviction into a portfolio weight. For each stock, you estimate:

• The upside scenario and its probability (how big is the opportunity if the thesis plays out?)

• The downside scenario and its probability (what happens if it doesn’t?)

• The expected payoff: (upside × probability) – (downside × probability)

Stocks with high expected payoff and high Q-score get higher allocations. Stocks where you are less confident or where the asymmetry is thinner get smaller allocations. Stocks where you have conviction on Q but are still waiting for price to improve stay on the watch list they are not bought just to fill a slot in the portfolio.

The disciplined application of CAP is what separates the +18.5% portfolio from the -8.5% portfolio using the exact same 10 stocks.

Part 6: The Leaderboard — Who Made the List in 2016?

Now let us look at the actual companies that appeared in the 21st Study.

Top 10 Fastest Wealth Creators, 2011–2016:

Top 10 Most Consistent Wealth Creators, 2006–2016 (10 consecutive appearances): Asian Paints, Kotak Mahindra Bank, Sun Pharma, Titan Company, Bosch, HDFC Bank, Axis Bank, Dabur India, Nestle India, Cummins India.

Top 10 Wealth Destroyers, 2011–2016: MMTC, NMDC, BHEL, ONGC, Jindal Steel, Vedanta, SBI, NTPC, SAIL, Coal India — seven of the ten were global commodity businesses.

Part 7: Nine Years Later — The Audit Nobody Has Done

Now comes the part that makes this study extraordinary in hindsight. Let us trace every category forward.

The Fastest Wealth Creators: A Divided House

The ten fastest companies of 2011–2016 had one thing in common: explosive stock price appreciation over the previous five years. Nothing else. Some had passed the QGLP filter. Others had not. The results after 2016 were a perfect natural experiment in what QGLP actually predicts.

Bajaj Finance: The QGLP Archetype

In December 2016, Bajaj Finance had a market cap of ₹373 billion. Sixty percent CAGR over five years. Most analysts thought the growth was peaking.

Today, Bajaj Finance’s market cap is approximately ₹4 trillion — more than 10x its 2016 level, delivered over just nine years. That implies a sustained CAGR of roughly 34% from December 2016 onwards, through demonetisation, the NBFC crisis of 2018, Covid, and three RBI governor changes.

Why? Because Bajaj Finance scored near-perfect on QGLP. Quality of business: India’s dominant consumer lending franchise, a monopoly in specific retail segments. Quality of management: Rajeev Jain built one of the most analytically rigorous risk management systems in Indian financial services. Growth: India’s formal credit market was structurally underpenetrated. Longevity: switching costs in lending relationships are real and durable. Price in 2016: at P/E of 29x, it was not cheap — but it was pricing growth that actually arrived.

The Kelly insight: Bajaj Finance was a big bet situation. Edge (proprietary understanding of the underpenetration thesis) + asymmetric payoff (massive upside, limited downside given business quality). Those who applied the CAP framework and sized it meaningfully made life-changing returns.

Vakrangee: When Q = 0, Nothing Else Matters

Vakrangee delivered a 63% CAGR during 2011–2016. It rode India’s digital India and e-governance narrative, setting up rural kiosks to deliver banking, insurance, and government services in underserved areas. The market loved the story.

By January 2018, the stock had climbed further — to ₹515 per share, making it a 1,000-bagger from its lows. Then, in a single month, it fell from ₹515 to ₹36. The trigger: a wave of auditor resignations. More than 30 auditors resigned in six months. What followed was one of the most spectacular corporate implosions in Indian market history.

The QGLP post-mortem is instructive. Quality of management was the failure point. There were red flags as early as 2014–2015 — unusually high promoter pledging, aggressive accounting for franchise network numbers that could never be independently verified, and a business model that relied heavily on government contracts without transparent operational data. Investors who applied a rigorous Q-filter would have stayed away. Those who saw a fast-moving stock in a buzzing sector and allocated based on momentum paid the price.

The Kelly lesson: without edge (you did not actually know the business was sound), you had no business making a large allocation, regardless of what the price chart said.

Welspun India: Quality Breaks At The Seams

Welspun India’s 88% CAGR between 2011 and 2016 put it at the very top of the fastest list. India’s largest home textiles exporter. Major supplier to Target, Walmart, and Bed Bath & Beyond in the United States. Revenues of ₹55 billion by 2016.

The collapse came in August 2016 — the same month the study was in final preparation. Target Corporation announced that it had discovered Welspun had been selling sheets labelled as Egyptian cotton that contained none at all. The contract, worth approximately ₹7 billion annually, was terminated immediately. Walmart followed. The stock lost 42% of its market value in three days, wiping $740 million off the balance sheet.

The QGLP analysis reveals the fault line: Quality of Management. The mislabeling was not an accidental supply chain error — it was a deliberate, sustained substitution over nearly two years. This is a governance failure of the most fundamental kind. A company willing to defraud its largest customer for margin improvement has a management team that will, when sufficiently pressured, defraud its investors too.

The business was fine. The management was not. Q = 0. The study’s framework, applied rigorously, would have caught this.

Ajanta Pharma: The Good Business That Hit Its Longevity Wall

Ajanta Pharma delivered 121% CAGR between 2011 and 2016. At ₹2x per share in 2011, it was one of the most explosive wealth creators in Indian pharma history. The thesis was straightforward: a focused niche pharma company growing aggressively in branded generics in Asia and Africa, away from the brutal US generics price war that was destroying bigger players.

After 2016, the stock essentially stagnated for three years. From a peak near ₹2,000 in 2016–2017, it traded sideways until 2019. The business continued to grow — revenue and earnings kept compounding — but the market had re-rated the growth prospects. The high-growth, low-competition window in African and Asian markets began to narrow. Competitors caught up with similar product strategies. The Longevity component of QGLP was being questioned by the market.

By 2025, Ajanta Pharma’s market cap sits at roughly ₹372 billion — about 3x its 2016 level, representing a CAGR of approximately 13–14%. Respectable. But nothing close to the 121% of the preceding five years.

The lesson: Longevity is the hardest part of QGLP to assess. When a company’s growth runway is long, the rewards are extraordinary. When the runway is shorter than expected, even a genuinely good business delivers mediocre stock returns because the high growth premium built into the valuation never fully materialises.

The Consistent Wealth Creators: A Different Story Entirely

Now compare the fastest list to the consistent list. Asian Paints, HDFC Bank, Titan, Kotak Mahindra Bank — these names appeared in 10 consecutive Wealth Creation Studies between 2006 and 2016. Not the flashiest names. Not the ones generating cocktail party conversation.

Asian Paints compounded from roughly ₹250 in 2016 to over ₹2,500 by 2022 — a 10x return over 6 years — before recent headwinds from Birla Opus competition. Titan tripled, then tripled again. Kotak continued its quiet compounding. These were the stocks that appeared average in any given year but extraordinary over any meaningful time horizon.

The QGLP observation: all of these companies scored high across all four criteria, consistently. The Longevity was real — brands, distribution networks, and customer loyalty take decades to build and are nearly impossible to replicate quickly.

Part 8: The Most Counterintuitive Finding

Now here is the twist that makes this whole exercise genuinely surprising.

Look at the Wealth Destroyers of 2011–2016: NMDC (–19% CAGR), BHEL (–23%), ONGC (–6%), Jindal Steel (–39%), SBI (–7%), NTPC (–8%), SAIL (–24%).

These were labelled wealth destroyers. They were commodity companies, PSUs, and cyclicals in a down cycle. Conventional wisdom said stay away.

What happened to them after 2016?

NMDC — ranked #6 on the Most Consistent Wealth Creators list in the 2024 Wealth Creation Study with a 26% CAGR over 2019–2024. From destroyer to consistent creator.

Jindal Stainless — ranked #3 Fastest Wealth Creator in 2019–2024 with a 77% CAGR. The same company that was a top wealth destroyer in 2011–2016 became one of the ten fastest wealth creators in India over the subsequent five years.

SBI — ranked #5 Biggest Wealth Creator in 2019–2024. India’s largest bank, once dismissed as a permanently broken public sector institution, created ₹4.176 trillion in shareholder wealth in the five years to 2024.

What changed? Not the companies. The cycle changed. Commodity prices recovered. Credit cycles turned. India’s infrastructure spending boom created demand for steel, energy, and mining output. The Bruised Blue Chip dynamic (discussed in the 29th Study) applied perfectly: these were quality businesses in a down cycle, not structurally impaired businesses. Those who bought them at the depths of the 2016 pessimism made extraordinary returns.

The 21st Study’s framework did not specifically flag these as buys. But it contained the tools to see them clearly: a business that scores highly on Q (proven track record, dominant market position) but is currently suffering on G (cyclical earnings decline) and trading at deeply depressed P is exactly the high-asymmetry, analytical-edge situation where Kelly says: bet big.

Part 8.5: The Study’s Hidden Forward-Looking Signals

The 21st Study is primarily a retrospective — it looks backward at 2011–2016 data. But scattered throughout the data section were several implicit forward-looking signals that, if you were reading carefully, pointed clearly at what was coming next.

Most readers missed them. Here they are, with the benefit of nine years of hindsight.

Signal 1: The PSU Contrarian Call

In Section #7 (Ownership Analysis), after cataloguing how PSUs had been catastrophic wealth destroyers with only 4% of total wealth created, the study included a Key Takeaway that read almost like a contrarian buy thesis:

“Can industrial recovery and government focus lead to mean reversion for PSUs? Fortunes of many PSUs hinge on performance of the economy, especially the industrial sector — Coal India, BHEL, SBI, SAIL, etc. Measures to boost industrial recovery — ‘Make in India’, rate cuts — bode well for the fortunes of such PSUs. Further, the government too is focused on reviving PSUs e.g. merger of SBI associate banks. These, coupled with low valuations of PSUs, hold the potential to trigger mean reversion in Wealth Creation by PSUs.”

This is extraordinary in retrospect. The study was identifying the exact set of companies that became the next decade’s outperformers. The 29th Annual Wealth Creation Study (2024) confirmed the reversal dramatically: SBI (#5 Biggest), NMDC (#6 Consistent Creator), Jindal Stainless (#3 Fastest). The PSU mean reversion trade was implicit in the 2016 data — and the study explicitly flagged it.

Signal 2: The Hidden Gem List

Section #10 of the study is titled “Those Who Missed the List” — specifically a sub-section on “The Fast Who Didn’t Make It Big.” These are companies that delivered strong 5-year price returns but were too small by market cap to qualify for the top 100. It is, in effect, a hidden watchlist of tomorrow’s wealth creators.

Top of the list: Solar Industries at 43% CAGR for 2011–2016, with only ₹52 billion in wealth created — too small. The stock was trading around ₹800 in December 2016. Here is what happened next:

• Solar Industries pivoted from industrial explosives into India’s defence manufacturing revolution — rockets, propellants, composite materials, drones

• The stock hit an all-time high of ₹17,820 in June 2025

• That is a 22x return in under 9 years from the date of the 21st Study

The rest of that hidden list was equally compelling:

The QGLP filter would have helped select from this list. Solar Industries had strong Q (niche business, government client, professional management), genuine G (defence spending secular rise), credible L (once you hold a government explosive supply contract, you hold it for decades), and at ₹800 in late 2016, an extremely attractive P.

Signal 3: The Mini-to-Mid Pattern as a Hunting Framework

Section #8 analysed market cap crossovers. During 2011–2016, 67 companies moved from Mini to Mid category, generating an average 39% CAGR versus 5% for the Sensex. The study’s Key Takeaway was simple: “Mid category: A good place to hunt for Wealth Creators.”

This structural observation has held true in every subsequent study period. Small companies in large addressable markets with honest management and capital discipline consistently punch above their weight. The framework for finding them hasn’t changed.

Part 9: Applying the Framework to 2026 — A Focused Investor’s Lens

So where does this leave us today?

India’s markets have corrected meaningfully from their September 2024 peaks. The Nifty is off roughly 12–15% from highs. Small and mid-cap stocks have seen deeper cuts. FII outflows have been significant. Earnings growth momentum has slowed in several sectors.

In short: this is the environment the Focused Investing framework was designed for. Prices are more attractive. The noise is louder. And the temptation to diversify into safety and mediocrity has never been stronger.

Here is how I am thinking about building a focused portfolio using the QGLP + CAP lens in 2026:

The Q-filter first. Before you look at a chart or a price, ask: is this business one I would want to own privately for a decade? Does the management have a long, verifiable track record of honest capital allocation? In India’s market right now, several sectors pass this filter readily — private banking, select consumer brands, IT services companies, and healthcare businesses with deep R&D moats.

Then G — but assess the longevity of G. India’s credit cycle is in the early-to-middle stages of a structural expansion driven by formalisation, digitisation, and a rising middle class. Companies with exposure to this secular G — consumer lenders, insurance, wealth management — have a long runway. Capital goods and manufacturing businesses riding the PLI and infrastructure capex cycle also have genuine G, but the cycle-dependence of G needs to be assessed honestly.

L is the differentiator. In a market where nearly everything looked like it had runway in 2022–2023, L is now the test that matters. Which of the growth companies actually have durable competitive advantages — and which were simply beneficiaries of a liquidity-driven expansion in multiples? Businesses with genuine moats — proprietary technology, deep distribution, regulatory protection, or brand pricing power — will sustain their CAP through the next cycle. The others will disappoint.

P — now, finally, is more interesting. After two years of elevated valuations, several genuinely quality companies are available at prices that represent fair-to-attractive value. The QGLP checklist-passers that were untouchably expensive at 70–80x earnings are at 40–45x. Not cheap — but the long-term compounder math starts to work at these levels.

For position sizing — the CAP discipline. The stocks where you have highest conviction across all four criteria get your largest allocations. Where you have high Q and G but are uncertain about L, you still hold the position but at lower weight. Where price is compelling but Q is questionable, you stay out — no matter how good the chart looks.

A hypothetical focused portfolio for 2026 might look like: 3–4 private banking positions anchoring the portfolio at 35–40% combined weight; 2–3 consumer discretionary names (aspirational India, not FMCG defensives) at 20–25%; 2 IT services names with genuine transformation exposure at 15–20%; 1–2 healthcare names with strong domestic branded generics at 10%; and optionally, 1–2 manufacturing/capital goods names for cycle exposure at 10%. This is 12–15 positions — squarely in Focused Investing territory.

The critical discipline: do not add to the portfolio just to diversify. Each new position must earn its place by either improving the portfolio’s expected return or genuinely reducing a correlated risk. Adding a 16th position because the market just corrected a random sector is not diversification — it is the expensive illusion of safety.

Part 10: The Meta-Lesson

Looking back at December 2016 — in the middle of demonetisation chaos — the 21st Study’s most important message was not about specific stocks. It was about process.

The investors who outperformed over the subsequent nine years were not those who happened to be in the right sector. They were those who:

1. Maintained a clear portfolio goal (outperform meaningfully, not beat by 1–2%)

2. Applied a rigorous quality filter before any analysis of price or momentum

3. Sized their best ideas at meaningful weights — not hidden at 1–2% each

4. Monitored their holdings actively and updated their thesis honestly when facts changed

Bajaj Finance rewarded those who ran this process. Vakrangee punished those who skipped step 2. Welspun India reminded us that even past performance cannot substitute for present governance assessment.

The 2016 study was titled “Power of Allocation in Wealth Creation.” But the deepest insight was simpler: process is the only sustainable edge.

Charts do not tell you whether management will defraud their customers. Momentum does not tell you whether a growth story has three years of runway or fifteen. Only genuine analysis — the kind that produces real conviction, not just a comfortable reason to buy — creates the foundation for a meaningfully sized position that you will hold through volatility.

That is the Focused Investor’s advantage. It is not a clever formula. It is the patience to do the work, the discipline to apply the filter, and the conviction to size accordingly when both Q and asymmetry align.

We are in one of those moments right now.

Data Sources: Motilal Oswal 21st Annual Wealth Creation Study (December 2016); Motilal Oswal 29th Annual Wealth Creation Study (December 2024); Screener.in; company annual reports.

⚠️ This post is for educational purposes only and does not constitute investment advice. The companies mentioned are for illustrative purposes and analysis of historical data. Please do your own research and consult a SEBI-registered financial advisor before making investment decisions.

If this was useful, forward it to one serious investor in your circle. And if you have not already hit subscribe below. This is the kind of work we do here every week.

Subscribe now

Fast-forward to today, and we’re witnessing a modern gold rush: the explosive rise of artificial intelligence. Billions are pouring into AI models, chips, and applications, chasing the next big breakthrough. But as value investors, we must ask: Where lies the moat? Where is the predictable prosperity? Enter the “picks and shovels” of AI the infrastructure that powers it all: the data centers humming with energy, the copper wires transmitting signals, the cooling systems preventing meltdown, and the uranium fueling nuclear reactors for insatiable power demands. This is not about picking winners in the AI lottery; it’s about owning the tools that make the game possible.

In this post, we’ll explore why investing in AI’s backbone through vehicles like the ETF (embodies this timeless strategy, offering a path to compounding wealth amid the hype.

Read more

but now we have upped the game for our paid subscribers, you get a full fledged internet companies virtual portfolio , all automated on a single page refreshed weekly

The new Momentum Dashboard expands the scope and usability of the original idea.

Instead of tracking only internet companies, it now focuses on:

• broader leadership trends

• systematic momentum signals

• clearer ranking of strength

• faster decision support

What the Dashboard Actually Shows

At its core, the system identifies stocks exhibiting positive weekly momentum.

When the signal is ON, the trend remains healthy.
When the signal turns OFF, the trend is weakening.

No opinions.
No forecasts.
Only observable behaviour.

This simplicity is intentional.

Read more

The Power of the “Inversion”

Charlie Munger always said, “Invert, always invert.” Most traders ask, “How do I make the most money this month?” The Tankrich system asks a much more important question: “How do I avoid being decimated?” By utilizing a systematic “In/Out” signal for volatile assets like Bitcoin, Silver the practitioner is practicing Capital Preservation. It is the recognition that in a game of high variance, the winner is often the one who simply refuses to play during the typhoons. This works for GOLD too cause it can do nothing for years

The Math of the “Fat Tail”

We live in a world of Non-Ergodicity. In plain English: if you go bust once, you are out of the game forever. Tankrich’s focus on Trend Following is an acknowledgement of “Fat Tails.” It doesn’t try to predict the bottom; it waits for the trend to prove itself.

If you have a process that is backtested, disciplined, and removes the "Self" from the equation, you have already won half the battle.

The Tankrich Signals platform it is an extension of a math-driven, trend-following philosophy designed to keep investors on the right side of the market.

Refreshed every week

How to Interpret

1. WAKE UP - The model has detetcted a trend

2. STAY PUT - Trend persists

3. RUN AWAY - Trend ends

4. HOLIDAY BREAK - Waiting for Trend

A Necessary Warning on the Limits of Models

In the spirit of Charlie Munger, I must remind you that a tool is only as good as the hands that wield it. While the systems discussed at Tankrich Signals provide a logical filter to navigate the “fat tails” of the market, they are not a substitute for your own independent thinking. No mathematical model, no matter how elegant or backtested, can account for the “Unknown Unknowables” or the sheer unpredictability of human folly on a global scale.

One must never mistake the map for the territory. The signals provided are a reflection of past probabilities, not a crystal ball for future certainties. You should assume that the risk of loss is permanent and that markets can remain irrational far longer than you can remain solvent.

Bookmark and consider subscribing as more stuff is coming your way!

Subscribe now

A comprehensive, fundamental analysis tool for equity research. Upload Excel files from screener.in (note you need to use their basic file, so if you use custom file please change it)

Before using tool do this while logged in

1. go to https://www.screener.in/excel/

2. click RESET customisation

   

3. download file of company you want to analyse

   

4. Upload on free dashboard

   

Free Dashboard

and get instant, deep financial analysis with advanced investment frameworks.

Core Financial Analysis

• Complete Financial Statements (P&L, Balance Sheet, Cash Flow)

• Growth Metrics (CAGRs: 3yr, 5yr, 7yr, 10yr)

• Profitability Ratios (ROE, ROCE, ROIC, Margins)

• Efficiency Metrics (Asset Turnover, Working Capital, CCC)

• Leverage Analysis (Debt-to-Equity, Interest Coverage)

Advanced Frameworks

• Quality Score - 100-point comprehensive scoring system

• Red Flags Detection - 7 balance sheet health checks

• DuPont Analysis - ROE decomposition into components

• Moat Analysis - Competitive advantage indicators

• Capital Allocation - Management quality grading

• Value Migration - Business trajectory analysis

• Earning Power Box - 2x2 growth vs cash matrix

• CAP Analysis - Competitive advantage period estimation

• Capex Split - Maintenance vs growth capital allocation

• Incremental ROIC - Returns on new capital deployed

• RM Sensitivity - Raw material cost vulnerability

• Buffett’s $1 Test - Capital allocation effectiveness

• FLOAT Detection - Business model with customer funds

Visualizations

• Revenue & Profit trends

• Margin evolution

• Returns analysis (ROE/ROCE)

• Cash flow breakdown

• Quarterly performance trends

• CAP analysis chart

Additional Features to be built

• Quarterly Analysis - QoQ and YoY growth trends

• Comparison Mode - Compare 2-3 companies side-by-side

• Print Support - Print-optimized layouts

• Export - Save analysis as PDF

How to Use

1. Export Data from Screener.in

1. Go to screener.in

2. Search for any company

3. Click on “Export” button

4. Download the Excel file

2. Upload to Dashboard

1. Open the Tankrich Dashboard

2. Click “Upload Excel from Screener.in”

3. Select your downloaded file

4. Analysis appears instantly!

What Each Section Tells You

Overview Tab

• Quality Score: 100-point rating across 5 dimensions (profitability, returns, cash flow, balance sheet, growth)

• Red Flags: Automatic detection of balance sheet issues

• Growth Metrics: Historical CAGRs for revenue and profit

• Returns: Latest year profitability ratios

How to Use New Features

Quarterly Analysis:

1. Navigate to “Quarterly” tab

2. View recent quarters’ performance

3. Check QoQ and YoY growth trends

Comparison Mode:

1. Load your first company

2. Click “Add for Comparison” button

3. Upload 1-2 more companies’ Excel files

4. Navigate to “Compare” tab to see side-by-side metrics

5. Use “Clear All” to reset

Print/Export:

• Click “Print” to get print-optimized view

• Use browser’s “Save as PDF” option

• Export button available for future PDF generation

Statements Tab

Complete financial statements with 10 years of historical data

Quarterly Tab

• Performance Trends: Quarterly revenue and profit visualization

• QoQ Growth: Quarter-over-quarter growth rates

• YoY Growth: Year-over-year comparisons

• Latest 8-10 quarters of detailed data

Analysis Tab

• DuPont Analysis: Understand what drives ROE (margins, efficiency, or leverage)

• Efficiency Metrics: How well the company uses its assets

• Leverage: Debt levels and coverage ratios

Frameworks Tab

• Moat Detection: Does the company have sustainable competitive advantages?

• Capital Allocation: How well does management deploy capital?

• Value Migration: Is value flowing to or from this business?

• Earning Power Box: 2x2 matrix positioning (growth vs cash generation)

Advanced Tab

• CAP Analysis: Competitive advantage period - how long can high returns last?

• Capex Split: Maintenance vs growth capex estimation

• Incremental ROIC: Are new investments creating value?

• RM Sensitivity: Vulnerability to raw material price changes

• Buffett’s $1 Test: Is management creating value with retained earnings?

• FLOAT Detection: Does the business benefit from customer funds?

Compare Tab (appears after adding companies)

Side-by-side comparison of key metrics across multiple companies

Charts Tab

Interactive visualizations of all key metrics over time

Technical Details

• 100% Client-Side: No data is sent to any server

• Privacy First: All processing happens in your browser

• No Installation: Works directly

My mission is to help mom and pop investors, to help me consider upgrading to paid

Subscribe now

Read more

Aarti Pharmalabs Limited (APL) is a demerged pharmaceutical arm of the Aarti Industries group (spun off in 2022) with a focus on active pharmaceutical ingredients (APIs), intermediates, and contract development & manufacturing (CDMO/CMO) services¹. The company operates three main business segments, each contributing roughly one-third of revenues: Xanthine Derivatives, APIs & Intermediates, and CDMO/CMO services².

APL is India’s largest producer of Xanthine derivatives (caffeine and related compounds) and in fact the only Indian manufacturer in this niche, holding an estimated 15–20% global market share in caffeine supply³.

It meets about 80% of India’s domestic caffeine demand⁴, making it a strategic supplier to beverage and pharma companies. The remaining two segments leverage Aarti’s chemical expertise in pharmaceuticals: the company has commercialized 55 APIs to date (with a strong presence in high-potency oncology and steroid APIs) and supplies over 500 customers across 50+ countries⁵.

The API & Intermediates division contributes ~44% of revenue, focused on chronic therapeutic areas like anti-diabetic and anti-cancer APIs, where APL has deep capabilities (including 50+ US DMFs filed and multiple EU CEP certifications)⁶. Meanwhile, the CDMO segment (13% of revenue in FY25²) provides end-to-end custom synthesis for innovator pharma clients, from route development to commercial manufacturing.

APL’s CDMO business specializes in small-molecule NCEs and complex intermediates (including HPAPIs via capabilities like cryogenic reactions and hydrogenation), working with numerous global pharma innovators. This segment has been growing rapidly post-demerging, benefiting from a “China plus one” outsourcing trend and Aarti’s long track record in chemistry services⁷.

Read more